Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
NSCLC
.
Show all posts
Showing posts with label
NSCLC
.
Show all posts
Thursday, August 8, 2013
Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC
›
We know that, Afatinib ( INN ; trade name Gilotrif , previously Tomtovok and Tovok ) is an approved drug against non-small ...
Thursday, October 18, 2012
Synta announces results from ganetespib Phase 2b trial on NSCLC
›
In continuation of my update on Ganetespib .... "The preliminary results from GALAXY indicate that the addition of ganetespib t...
1 comment:
›
Home
View web version
